Will Orent


Will Orent joined the T1D Fund in January 2023 as an Associate from DeciBio Consulting, a California-based life sciences strategy consulting firm with a device and diagnostics venture fund, where he focused on due diligence support for private equity, investment banking, and venture capital as a Life Science Expert.


Prior to VC, Will worked at the intersection of academia and private drug development at the Lou Gherig Center at Columbia University Medical School working on clinical trials in ALS (including for the recently approved therapy Tofersen). Will holds a PhD in Immunology from Harvard Medical School where he did dissertation work in autoimmunity with David Sachs and a B.A. in Studio Art from The School of the Museum if Fine Arts / Tufts University.